$TELA

Getz Heather C purchased $10K of TELA

Getz Heather C (Chief Executive Officer) purchased 15,000 shares of TELA Bio, Inc. (TELA) at $0.70 on 2026-08-14.

Original reporting
SEC EDGAR · Getz Heather C
Published Aug 17, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TELA
Bullish
medium confidence
Mentioned
$TELA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TELABullishLow
01

Why it matters

The newest fact is the CEO’s open-market purchase details (15,000 shares at $0.6978) and the post-transaction holdings (520,000 shares), with no pre-arranged 10b5-1 plan.

02

Market read

Traders may treat the buy as mild bullish sentiment, but it is unlikely to be a standalone driver without accompanying company-specific fundamentals.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, whether other insiders sold, or whether the company has upcoming catalysts that would dominate price action.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

This is an SEC Form 4 insider transaction disclosure for TELA Bio, Inc.

Company-level read

Ticker impact

$TELABullishMedium confidence
Context

TELA Bio CEO Getz Heather C filed a Form 4 for an open-market purchase of 15,000 shares at $0.6978 on 2026-08-14.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and small given the disclosed size and lack of 10b5-1 plan.

Evidence & confidence

Form 4 insider purchases can support bullish sentiment, but this disclosure does not include guidance, trial results, contracts, or regulatory actions that would materially reprice the stock.

Market effects

No clear sector read-through because the disclosure is limited to an individual insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification rather than a strong fundamental signal, especially without a stated thesis in the filing.

Key entities

  • TELA Bio, Inc.

    Company whose CEO filed the insider purchase Form 4.

  • Getz Heather C

    Chief Executive Officer and director who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TELAMed

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

TELA Bio reported Q2 2026 revenue of $19.3M, down 4% YoY, driven by declines in OviTex PRS unit volumes and price-mix headwinds. International revenue grew 26% YoY, while gross margin improved to 72%. Net loss was $11.3M, and cash reserves decreased to $30.4M. Management cited competitive pressures and slower sales rep productivity as challenges, while highlighting market share gains in hernia products and plans to reduce costs.

$TELAMed

TELA Bio, Inc. (TELA): Results of Operations and Financial Condition

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results fo